Unexpectedly, the synthetic antioxidant MnTBAP was found to cause a rapid and reversible downregulation of CD4 on T cells in vitro and in vivo. This effect resulted from the internalization of membrane CD4 T cell molecules into clathrin-coated pits and involved disruption of the CD4/p56
INTRODUCTION
Mn(III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP) is a cell-permeable synthetic antioxidant with superoxide dismutase-like activity. This molecule neutralizes superoxide 1 in both extracellular and intracellular compartments. 2 Tested in vivo, MnTBAP is nonimmunogenic, is non-toxic, and shows significant therapeutic benefits in diminishing inflammation in various models of injuries 3, 4 or of organ transplantation, 5 or by reducing effector immune responses against a virus challenge. 6 In such models, the effects of MnTBAP have been attributed to reactive oxygen species (ROS) inhibition, which is its main mechanism of action. However, previous results from our laboratory suggested that MnTBAP could also act on T cells directly. Indeed, we observed that the conversion of naive CD4 + T lymphocytes into Foxp3 + regulatory T cells (Tregs) was hampered in the presence of 200 mM MnTBAP in vitro. 7 This prompted us to examine in greater detail the effects of MnTBAP on CD4 + T cells. In the present study, we report for the first time that MnTBAP, can reversibly downregulate the CD4 molecules on T cells. As a primary receptor for HIV-1, CD4 is one of the most studied molecules in the human body. The CD4 T cell-surface glycoprotein mediates optimal T cell receptor (TCR) signaling during major histocompatibility complex (MHC) class II (MHCII) antigenic activation by helping in Src-tyrosine kinase p56
Lck recruitment 8 
to facilitate the activation of helper T cells. Interactions between CD4 and p56
Lck stabilize CD4 at the plasma membrane by anchoring CD4 into distinct microvilli microdomains that constitute the primary contacts between T cells and antigen-presenting cells (APCs). 9 A tight regulation of CD4 cell-surface expression is essential for adaptive immunity, as it ensures prospective scanning of MHCII by CD4 on the surface of APCs, which is pivotal for T cell priming, 9 and enables a productive signal transduction during T cell activation. It is well established that CD4 + T cells also regulate the pathogenesis of autoimmune diseases, allergies, graft-versus host disease, and rejection processes in organ transplant. [10] [11] [12] [13] Furthermore, CD4 + T cells, which are essential for protective and memory immunity against viruses initiated by infection or by vaccination, 14 are also key players in the induction of adverse immune responses following viral gene transfer therapies. 15, 16 Thus, to gain insights in the effects of MnTBAP, we explored the mechanism of CD4 deprivation at the cell surface of T cells upon MnTBAP treatment and examined the functional effects on CD4-dependent T cell functions.
Indeed, we demonstrate here that MnTBAP rapidly and reversibly downregulates CD4 on T cells, disrupting the CD4/p56
Lck complex. MnTBAP-treated cells cannot be transduced with gp120-mediated lentiviral vectors. A short MnTBAP treatment at the time of antigen priming provokes immune unresponsiveness to OVA peptide immunization and reduces specific immunological responses to adenoassociated viral vector (AAV) gene transfer. This new immunomodulatory feature of MnTBAP could be exploited to provide short-term treatment for long-term benefit in a large set of therapeutic or immunopathological conditions.
RESULTS

CD4 at the Cell Surface of T Cells Is Reversibly Internalized upon MnTBAP Treatment
To study the effects of MnTBAP on CD4 + T cells, purified splenic CD4 + T cells from C57BL/6 mice were treated in vitro for 2 h with increasing doses of MnTBAP (100-400 mM). A gradual and dosedependent decrease of the CD4 cell-surface co-receptor was observed, with almost complete disappearance of the CD4 + T cell population at the highest dose of MnTBAP tested ( Figure 1A ). At 400 mM, MnTBAP reduced by 8-fold the expression of CD4 at the surface of T lymphocytes ( Figure 1B ). This effect was not due to the induction of cell death, as measured by eFluor 780 positivity ( Figure S1A ). Subsequent experiments were conducted with 400 mM MnTBAP, which triggered consistently high and non-toxic loss of CD4 T cell-surface molecules. The kinetics of CD4 downmodulation by MnTBAP, investigated with time-lapse microscopy recordings over a period of 4 h of treatment, showed a rapid drop of fluorescence starting sooner than 2 min with sustained decay (Figure 1C , gray line) compared to control ( Figure 1C , black line). Downregulation was maximal by 2 h of MnTBAP treatment, reaching a half-time (50% decrease of cell-surface CD4) of approximately 30 min. The CD4 downregulation was accompanied by the dissociation of the CD4/p56
Lck complex in the cells. Less p56 Lck was coprecipitated with CD4 in splenic T lymphocytes after 2 h of treatment with MnTBAP compared to controls ( Figure 1D ), whereas similar amounts of p56
Lck and CD4 were detected on immunoblots of whole-cell lysates ("Lysates") from cells treated with or without MnTBAP ( Figure 1D ). Indeed, more than 3 times fewer p56 Lck molecules were CD4 associated after MnTBAP treatment ( Figure 1E ). In naive murine CD4 + T cells, p56 Lck was localized to the cytosol and at the plasma membrane, and p56 Lck localization did not change with MnTBAP treatment ( Figure 1F) . However, the distribution of CD4 molecules on CD4 + T cells was dramatically affected by MnTBAP treatment. In sharp contrast with the control condition in which the CD4 molecules were globally distributed throughout the cellsurface membrane ( Figure S1B , None), MnTBAP induced the disappeareance of CD4 from the cell surface and caused its redistribution in vesicles near the cell membrane (white arrowheads) and in the cell center (red arrowhead) ( Figure S1B , MnTBAP). The internalization of CD4 was accompanied by its incorporation into clathrin-coated pits, 17 as evidenced by CD4 and clathrin immunostaining and confocal microscopy analysis ( Figure 1G ). Untreated T lymphocytes displayed CD4 at the cell surface defining their shape ( Figure 1G , left, red signal) whereas clathrin was on the inside face of the membrane ( Figure 1G , left, green signal). In MnTBAP-treated cells, most cells had lost CD4 cell-surface expression in favor of a colocalization with clathrin molecules ( Figure 1G , right, yellow spots; Figure S1C , Merge). Further evidence that the MnTBAP-induced CD4 internalization is dependent on the formation of clathrin-coated pits was provided by experiments in hypertonic conditions. Hypertonic cell-culture medium containing 0.45 M sucrose blocks clathrindependent endocytosis 18 and prevented the CD4 downregulation induced by MnTBAP ( Figure 1H , Hypertonic), whereas CD4 could be internalized in iso-osmotic medium ( Figure 1H , Normal). Many of the receptors internalized by clathrin-coated pits are recycled to the cell surface and re-used up to several hundred times by the cells. 19 Reportedly, in transfected 293T cells, about 45% of internalized CD4 recycled back to the cell surface within 10 min. 20 As expected from recycling biology, CD4 internalization into clathrincoated pits induced by MnTBAP was reversible ( Figure 1I ): while 2-h treatment ("Treated") reduced almost 80% of CD4 cell-surface The levels of CD4 on murine and human T lymphocytes were similarly affected by 2-h treatment with 400 mM MnTBAP, with a 92% and 85% decrease compared to control non-treated cells for murine and human T cells, respectively (Figures 2A and 2B ). MnTBAP also reduced the cell-surface CD8 by a 30% and 40% decrease compared to control non-treated cells for murine and human T cells, respectively. No alteration of CD3 expressions was observed with MnTBAP treatment (Figures 2A and 2B ). Since CD4 is the primary entry receptor for HIV and mediated by gp120-CD4 interactions, we evaluated the functional consequences of MnTBAP-induced CD4 cell-surface decline in a model of HIV infection. We tested the transduction of primary human CD3 + T lymphocytes by gp120 HXB2 -enveloped (gp120 HXB2 -env) lentiviral vectors encoding GFP that transduce specifically CD4 + T cells (None, in Figure 2C , left panel). MnTBAP treatment strongly prevented virus transduction in all cells (MnTBAP, in Figure 2C , right panel, and Figure 2D ) in coherence with the reduced membrane CD4 described earlier ( Figure 2B ). Moreover, once again, we emphasize the reversibility effect of MnTBAP, as shown in Figure 1I , since 72 h after the MnTBAP removal, treated human T lymphocytes (MnTBAP, in Figure 2C , right panel) expressed the cell-surface CD4 to levels similar to that of the control non-treated cells (None, in Figure 2C , left panel). To examine whether MnTBAP could have a functional effect via CD4 in vivo, we used a well-characterized CD4-dependent murine immunization model with MHCII-restricted OVA peptides. In addition, CD8 + T cell responses were also determined in this model by the use of MHCI-specific peptides. MnTBAP is injectable and has already been administered to mice for its anti-oxidant effects. [3] [4] [5] Prior published data from a patent (U.S. patent no. 8598150 B1, 2013) provided indication on the effective and toxic ranges of MnTBAP in mice. However, a protocol for the use of MnTBAP in vivo to downregulate CD4 was not known and had to be established. Using a high-performance liquid chromatography (HPLC) technique, 21 we determined that the plasma concentration of MnTBAP in C57BL/6 mice rapidly declined over time after intraperitoneal (i.p.) injection of 80 mg/kg (data not shown), prompting a multi-administration schedule. The first protocol tested aimed to inhibit CD4 + T cells prior to, and after exposure to, the antigen in order to demonstrate the possibility of interfering with CD4 + T cell-mediated responses after immunization. This protocol included one MnTBAP injection 2 h prior to immunization and four daily injections post-immunization ( Figure 3A ). Immunization was conducted through subcutaneous (s.c.) OVA peptides or PBS injections with an adjuvant (IFA) ( Figure 3A and CD8 + T cell-mediated immunity following immunization. As these effects could be potentially immunosuppressive, a second protocol was designed to confirm the presumed reversible effect of MnTBAP by immunization with OVA outside the MnTBAP treatment window ( Figure 3C ). Mice injected with peptides 21 days post-MnTBAP administration ( Figure 3C ) were capable of mounting OVA-specific CD4 + and CD8 + IFN-g T cell responses as high as those in the PBS group ( Figure 3D ). Splenic cells from PBS-or MnTBAPtreated mice were assayed by flow cytometry for cell-surface expression of CD3, CD4, and CD8 ( Figures 3E-3G ). Significant downregulation of CD4 and CD8 by MnTBAP were shown to occur in vivo at day 4, with cell-surface levels being z80% and 90% of those seen in PBS-treated mice, respectively (Figures 3F and 3G). The CD4 and CD8 cell-surface levels recovered at day 8 and day 16 to levels similar to those of control mice, whereas the CD3 level remained unchanged with MnTBAP treatment throughout the study ( Figure 3E ).
Taken together, we show that, in mice, adaptive T cell immune responses to highly immunogenic antigens can be quelled by MnTBAP, provided that the vaccine is administrated within the MnTBAP treatment window in which a major effect on CD4 + T cells and a weaker effect on CD8 + T cells are observed. These results prompted us to investigate whether MnTBAP could be exploited in a challenging and therapeutic application involving strong CD4 + T cell-mediated immune responses.
MnTBAP Treatment Prevents Anti-transgene Immune Responses following Intramuscular rAAV Gene Transfer in Mice, Reducing CD8 + T Cell Infiltration and Muscle Damage
In gene therapy, cellular immune responses can be readily induced against transgene and vector following recombinant AAV (rAAV) gene transfer in mice. These immune responses lead to the loss of transgene-expressing cells and to the production of neutralizing antibodies against the rAAV capsid that prevent redosing the mice with the same vector. We previously established an immunogenic gene transfer model to follow transgene-specific CD4 + and CD8 + T cell responses following intramuscular (i.m.) rAAV1-mediated gene delivery in mice. In this model, the transgene is expressed at the membrane of skeletal muscle fibers and consists of the human a-sarcoglycan (SGCA) gene fused to the male HY gene sequences (SGCA-HY). When expressed from a cytomegalovirus (CMV) promoter, this transgene is highly immunogenic in female mice that are not tolerant to the male HY antigen. The i.m. injection of low doses of rAAV1 (2-5 Â 10 9 viral genomes [vgs] per injection, i.e., about 10 11 vg/kg) was sufficient to induce effector anti-transgene and anti-capsid T cell responses that are highly dependent on MHCII-dependent antigenic presentation and activation of transgene-specific CD4+ T cells. 15, 22 To determine whether MnTBAP could affect T and B cell immune responses induced by rAAV1 i.m. gene transfer, we implemented the protocol of MnTBAP administration used for OVA immunization ( Figure 4A ). The CMV-driven SGCA-HY transgene (rAAV1_CMV_SGCA_HY, 2.5 Â 10 9 vg per mouse) was delivered via i.m. injection in left tibialis anterior (TA) muscle, in the time window of MnTBAP administration, 2 h after the first MnTBAP injection ( Figure 4A ). Since MnTBAP is primarily a well-known antioxidant molecule, its contribution to reduce inflammation by the innate immune system, at the site of vector delivery, should also decrease the establishment of subsequent adaptive immunity. Indeed, there was no significant inflammation detected by light emission in the left PBS injected-TA of animals treated with PBS and MnTBAP, as shown in Figure S2A , following a chemical reaction of ROS with the luminolbased substrate L-012 ( Figure 4A ).
Moreover MnTBAP-treated mice presented clearly a very low total ROS level at the i.p. site of multi-injection, compared to PBS-treated mice ( Figure S2A ). In a similar way, rAAV1-injected muscles of MnTBAP-treated mice presented 4 days post-vector injection with a reduced inflammation compared to that of their control counterparts ( Figures S2B and S2C) . At the histological level 15 days after gene transfer, a reduced muscular inflammation in MnTBAP-treated mice (MnTBAP/rAAV1) coincided with the presence of a high number of preserved myofibers shown by H&E staining, strongly contrasting with the tissue destruction and generalized centro-nucleation of myofibers reflecting extensive tissue regeneration in control mice (PBS/rAAV1) (Figures 4B, left panels, and 4C). At the same time point, the i.m. administration of rAAV1_CMV_SGCA_HY vector in MnTBAP-treated mice led also to a lower level of CD8 + T cell infiltrate, but to robust and persistent SGCA transgene expression (Figures 4D and 4E, respectively), as measured by RT-PCR in TA of MnTBAP-treated mice, contrary to controls. Muscle immunohistology confirmed the presence, in control mice, of a strong CD8 + T cell infiltrate detected as disseminated brown spots throughout the muscle, while very few or no spots could be seen in MnTBAPtreated and naive mice (PBS/PBS), respectively ( Figure 4B , right panels). Concomitantly, spleens of mice were harvested to measure transgene-specific CD4 + and CD8 + T cell responses by the frequency of Dby-or Uty-activated IFN-g-producing cells, respectively. Preservation of muscle structure along with long-term maintenance muscle transduction in MnTBAP-treated mice correlated with the absence of transgene-specific CD4 + cell response detected at day 8 post-vector injection and the persistence of very low transgene-specific CD4 A notable obstacle for gene therapy using rAAV vectors is the induction in vivo of capsid-specific CD4 + and CD8 + T cell responses and anti-AAV neutralizing antibodies (NAbs), which not only may limit the duration of transgene expression following AAV gene transfer but also can completely prevent transduction of a target tissue when administering the same serotype. 23 The induction of antibodies to the AAV caspid is dependent upon innate immune activation and involves TLR9-mediated CD4 + T cell activation into TH1 effector cells. 24, 25 To assess the effects of MnTBAP on the induction of anticapsid antibodies following rAAV gene transfer, we designed a protocol in which the rAAV vector was this time intravenously (i.v.) injected to favor a higher exposure to the vector material of lymphoid tissues, which are critically involved in antigen presentation and in the initiation of the immune response to capsids, and rechallenged the mice with local i.m. injections of an rAAV bearing the same capsid serotype but a different transgene ( Figure 5A ). MnTBAP treatment for 5 consecutive days (days 0 to 4) at the same time as vector administration (day 0) successfully attenuated humoral immunity to viral capsid, since MnTBAP-treated mice produced no or significantly less specific anti-rAAV immunoglobulin G (IgG) compared to the control group, respectively, at day 21 and day 28 post-vector injections ( Figures 5B and 5C ). A second rAAV was injected 28 days after primary vector exposure ( Figure 5A ). The second vector bears the same serotype but encodes a secreted form of murine alkaline phosphatase (mSEAP) that can be quantified in blood samples as well as on tissue sections. The level of secondary-type anti-rAAV1 antibody titers, measured 10 days following vector reexposure (day 38), in the MnTBAP cohort was significantly lower compared to that in the control PBS group ( Figure 5D ). In addition, a higher transduction efficiency of injected muscle was observed, since a significant amount of mSEAP-positive fibers was detected, around 3 months after vector reexposure in the injected-TA muscle sections of MnTBAP-treated primed mice (TA MnTBAP/rAAV1) ( Figure 5E ). The amount of mSEAP-positive fibers observed was comparable to that in the positive control group of PBS-treated mice that had not been exposed to rAAV1 vector before mSEAP vector administration (TA PBS/ PBS) ( Figure 5E ). In contrast, similarly to contralateral non-injected muscles that did not stain at all (contralateral TA), only very few mSEAP-positive fibers could be seen in muscle sections of PBStreated mice that had been primed with rAAV1 vector (TA PBS/ rAAV1) and reinjected with mSEAP vector ( Figure 5E ). As expected, the levels of circulating mSEAP correlated with the number of muscle fibers positive for mSEAP ( Figure 5F ). Likewise, a significantly higher copy number of the readministrated vg was detected, 3 months after vector reexposure, in the injected-TA muscles of MnTBAP-treated mice compared to those of control mice ( Figure 5G ). Altogether, these results indicate that one short period of treatment with MnTBAP at the time of primary vector exposure appears to be effective at attenuating memory humoral immunity to rAA1 capsid proteins to levels that allow efficient preservation of a second vector of the same serotype from neutralization upon reexposure. That was not the case for PBS-treated primed mice, in which, upon secondary response to the same antigen, memory cells might have been rapidly activated 26 to produce NAbs to bind to the AAV capsid, resulting in the reduction of transduced target cells ( Figures 5E and 5F ).
DISCUSSION
Our data show for the first time that the synthetic anti-oxidant MnTBAP effectively, rapidly, and reversibly deprives T cells of extracellular membrane CD4 and, to a lesser extent, of CD8 and that this has functional antiviral or immunomodulatory impacts. Indeed, MnTBAP treatment of T cells prevents CD4-dependent gp120-mediated lentiviral transduction. In vivo, repeated administration of MnTBAP in mice prevents the induction of antigen-specific TH1 T cell responses and the production of neutralizing antibodies to rAAV.
The effects of MnTBAP on the downregulation of CD4 and CD8 are novel, since MnTBAP is otherwise known as a superoxide dismutase mimetic that prevents the induction of ROS. The mechanism involved here is rapid (maximum, 2 min) and leads to the internalization of cell-surface CD4 into clathrin-coated pits with possible reexpression at the membrane within hours up to a full recovery in less than a day. The mechanism concerns CD4 and CD8, but membrane levels of CD3 were unchanged. Upon antigenic recognition, TCR signaling is initiated by the phosphorylation of TCR tyrosine residues by a pool of pre-activated p56 Lck present in the cells, 27 and subsequent protein-protein interactions between p56 Lck and CD4
promote the distribution of p56 Lck to the TCR-peptide-MHC complex in the immunological synapse. 28 p56 Lck and its localization to the plasma membrane of T cells were not altered by MnTBAP treatment. However, the CD4/p56
Lck complex was disrupted. It is known that naive peripheral T cells from Lck À/À mice exhibit a normal phenotype, with the exception of reduced levels of CD4 on the cell surface, 29 and that myeloid cells lacking p56 Lck expression exhibit significant constitutive CD4 endocytosis. 30 Therefore, it is not clear at this point whether MnTBAP disrupts the CD4/p56 Lck , which causes internalization of CD4, or whether MnTBAP causes CD4 internalization, which dissociates the complex. MnTBAP was effective not only on murine cells but also on human cells in drastically reducing cell-surface CD4 and, to a much lesser degree, cell-surface CD8. The differential effects of MnTBAP on CD4 and CD8 might be explained by a less extensive association of CD8 coreceptor to p56 Lck compared to CD4. 31 In mice treated with MnTBAP, the disappearance of CD4
and CD8 was observed at early time points (day 4 but not day 8 or later). Presumably, the reduced CD4 and CD8 levels in T cells were also associated with disrupted interactions between CD4 or CD8 and p56
Lck , which could have perturbed antigen-induced TCR-mediated signaling and immunological synpase formation. Furthermore, the loss of CD4 localization to microvilli may disturb the initial phase of T cell activation ensured by CD4 as a scanning machinery to select for cells that have MHCII on their surface. 9 Therefore, MnTBAP is expected to inhibit the priming of T cells and the development of B cell responses with reduced effector T cells and antibody-secreting cells. The effects of MnTBAP on CD4 or CD8 downregulation have not yet been described elsewhere to our knowledge. However, MnTBAP is known to reduce acute viral infection when administered daily at a low dose of 5 mg/kg in a murine model of lymphocytic choriomeningitis virus (LCMV) infection. 6 These effects were ascribed to CD4 + T cell death mediated by an altered redox regulation of mitogen-activated protein (MAP) kinases. Our results suggest that LCMV priming defects could also have been induced by MnTBAP in this model.
The induction of immune tolerance is a daunting challenge in many conditions, including solid organ and hematopoietic stem cell transplantation, 32 as well as in gene therapy. 33 Our results provide a novel target for immunomodulatory strategies in gene therapy. In view of the crucial role of the CD4 co-receptor as a target for the onset and the maintenance (memory formation signal) of immune responses, 34, 35 the possibility to render this target surface molecule inaccessible during the priming of immune responses, as was shown here with MnTBAP, could be useful. As shown with OVA immunization, the MnTBAP treatment can effectively prevent T cell-mediated immunity but is transient and functionally reversible. Therefore, selective and not generalized immunosuppressive treatment could be devised, which is useful for gene therapy applications. MnTBAP could, thus, still allow the body to react to opportunistic infections contrary to common immunosuppressive drugs, 36 which penalize the entire immune system for unwanted activity of just a small fraction of its lymphocytes. Transient CD4 co-receptor modulation by MnTBAP was evaluated in the context of AAV-mediated gene transfer. Recent studies documented rAAVs as a tool of choice for gene therapy to treat genetic disorders because of their efficiency in vivo, leading to the market approval in Europe and the United States of several gene therapy drugs, including a rAAV1-based gene delivery in muscle. 37 rAAVs are non-inflammatory vectors but trigger immune responses to the AAV capsid and/or transgene capable of compromising long-term therapeutic efficacy. Novel strategies are, therefore, needed to be able to readminister the vector after a period of time to maintain therapeutic levels of transgene product in patients. 38 However, the neutralizing anti-capsid antibodies generated by the first rAAV vector administration limit vector redosing. 38 Immunomodulatory or immunosuppressive treatments that enable rAAV redosing present a great interest for gene therapy. Novel immunosuppressive agents such as nanoparticles loaded with rapamycin have been successfully used with rAAV gene delivery preclinical models to reduce rAAV capsid immunogenicity and to enable effective vector readministration. 36 Our study provides another alternative to reduce immune responses induced by rAAV gene transfer using a non-toxic, non-immunosuppressive agent at the time of vector delivery. MnTBAP not only reduced anti-transgene CD4 and CD8 T cell responses preventing muscle fiber destruction but also prevented the establishment of T cell and B cell immune responses against the rAAV1 capsid, enabling redosing with the same serotype. The control of anti-SGCA-HY immune responses obtained with MnTBAP was as efficient as previously obtained in this model by regulating direct antigenic presentation of the transgene using a microRNA 142.3p-regulated cassette. 22 This further argues that MnTBAP acts by blocking the priming of T cell responses against the AAV1 capsid and against the SGCA-HY transgene peptides. Advantageously, a brief period of MnTBAP treatment was sufficient to prevent the establishment of T cell immune memory, allowing for antigen reexposure. MnTBAP is not an approved drug for human use. Thus, further work is warranted to explore the pharmacological and therapeutic properties of MnTBAP or similar compounds, as well as other strategies leading to temporary CD4 downregulation. In addition, not only are the appealing properties of MnTBAP potentially useful for gene therapy, but it may also be exploited for autoimmunity or in any form of active immunopathology associated with excessive or undesirable immune responses. 26 
MATERIALS AND METHODS
Animals
Six-to 8-week-old female C57BL/6 mice were purchased from Charles River Laboratories (L'Arbresle, France). Mice were housed under specific pathogen-free conditions and handled in accordance with French and European directives. Protocols were conducted according to national and international ethical standards and were approved by the local ethics committee (C2EA-51).
In Vitro and In Vivo MnTBAP Treatments
MnTBAP (Calbiochem, San Diego, CA, USA; or Enzo Life Sciences, Farmingdale, NY, USA) was dissolved in 75 mM NaOH to constitute a 20-mM stock solution. MnTBAP was dissolved in the complete medium, used for in vitro treatment, containing RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/mL penicillin/streptomycin, 2 mM glutamax, and 50 mM 2-ME. Hypertonic medium, used to block clathrin-dependent endocytosis, is complete medium supplemented with 0.45 M sucrose. For in vivo treatment, the stock solution was diluted with PBS and administered at 80 mg/kg i.p. daily during 5 days. Control animals were injected with equivalent volumes of PBS.
Splenic CD4 + T Cell Isolation and Flow Cytometry Analysis
After mechanic disruption of the spleen, erythrocytes were eliminated by hypotonic shock with ammonium chloride potassium (ACK) lysing buffer. When indicated, splenic cell suspensions were directly submitted, without further purification, to staining with antibodies. CD4 + T cells were isolated from splenic cell suspensions by negative selection using a CD4 + T cell isolation kit (Miltenyi Biotec, Paris, France) followed by autoMACS (Miltenyi Biotec) magnetic sorting, according to the manufacturer's instructions. Purity of isolated CD4 + T cells was usually >95%.
For flow cytometry analysis, cell suspensions were first incubated, for murine cells, with anti-FcgRIII/II (Fc Block 2.4G2, BD Biosciences, Le Pont de Claix, France) monoclonal antibodies (mAbs) or, for human cells, with g-globulins from human blood (Sigma-Aldrich, StQuentin-Fallavier, France) for 10 min at 4 C and then stained for 30 min at 4 C in PBS, 0.1% BSA with Fc Block or g-globulins present, using saturating amounts of the following mAbs: rat anti-mouse CD4-Pacific Blue (RM4-5, BD Biosciences), hamster anti-mouse CD3-APC (145-2C11, BD Biosciences), rat anti-mouse CD8-Alexa Fluor 700 (53-6.7, eBioscience, Paris, France), mouse anti-human CD3-FITC (fluorescein isothiocyanate) (HIT3a, BD Biosciences), mouse anti-human CD4-APC (RPA-T4, BD Biosciences), and mouse anti-human CD8-Pacific Blue (RPA-T8, BD Biosciences). Gates for the different cell populations were set according to their corresponding isotype controls. Cell viability was determined by staining with 7-aminoactinomycin D (7-AAD; Sigma-Aldrich) or Fixable Viability Dye eFluor 780 (eBioscience). When indicated, samples were fixed with 1% paraformaldehyde. Samples were acquired on an LSR II flow cytometer (BD Biosciences), and data were analyzed with DIVA software (BD Biosciences).
CD4 Immunoprecipitation
Cells, harvested after a 2-h culture with or without MnTBAP, were resuspended in solubilization buffer containing 1% NP-40 (Sigma-Aldrich), 0.1 M (NH 4 ) 2 SO 4 , 20 mM Tris (pH 7.5), 10% glycerol, 25 mM NaF (Sigma-Aldrich), 1 mM Na 3 VO 4 (Thermo Fisher Scientific, Villebon-sur-Yvette, France), and 1Â protease inhibitor mixture (Roche, Basel, Switzerland). After 30 min of incubation under gentle agitation, cell lysates were centrifuged at 14,000 Â g for 30 min. Lysates were frozen in aliquots at À20 C or used immediately. Immunoprecipitation was performed by incubation overnight of lysates with rat anti-mouse CD4 (clone GK1.5, BioLegend, San Diego, CA, USA) under gentle agitation at 4 C. The antigen-antibody complex was then added to Protein A/G Resin slurry (Pierce, Thermo Fisher Scientific), incubated with gentle mixing for 2 h at room temperature, and finally microcentrifuged for 30 s. The pellet was washed five times with solubilization buffer, and the immunoprecipitated material was eluted by incubating the complex for for 2-5 min at 95 C-100 C in Laemmli sample buffer prepared without 2-ME. The immunoprecipitates and whole-cell lysates ("lysates") were electrophoresed in precast SDS-PAGE (10% polyacrylamide) gels (Bio-Rad Laboratories, Hercules, CA, USA), transferred to polyvinylidene fluoride (PVDF) membrane (Merck, Darmstadt, Germany), and probed with antip56
Lck rabbit antibody (Santa Cruz Biotechnology, Nanterre, France) followed by IRDye conjugated secondary antibody according to the manufacturer's instructions (LI-COR Biosciences, Lincoln, NE, USA). Blots of whole-cell lysates ("lysates") were stripped and reprobed with anti-CD4 (clone GK1.5, BioLegend) antibody and detected using the enhanced chemiluminescence (ECL) method with secondary antibodies coupled to horseradish peroxidase (Pierce). Chemiluminescent signals were digitally acquired with a Chemidoc Imaging System (Bio-Rad, Marnes-la-Coquette, France). Infrared fluorescence of the secondary antibodies was read on an Odyssey Imaging System, and quantification of bands was performed using the ImageStudio Lite software (LI-COR Biosciences).
Immunofluorescence Microscopy
After culture in complete medium with or without MnTBAP at 400 mM, murine splenic CD4 + T cells were collected and subjected to immunostaining as previously described. 7 Briefly, after adhesion on poly-L-lysine-coated slides (Thermo Fisher Scientific), cells were fixed in 4% paraformaldehyde for 5 min at 4 C and for 10 min at room temperature and were permeabilized with methanol for 6 min at À20 C. Cells were stained overnight with rat anti-mouse CD4-APC (BD Biosciences) or with unlabeled primary rabbit anti-mouse clathrin (Abcam, Paris, France) or p56
Lck (Santa Cruz Biotechnology) antibodies. These primary antibodies were then detected by staining with the goat anti-rabbit Alexa Fluor 488 or Alexa Fluor 594 secondary antibodies (Invitrogen, Carlsbad, CA, USA) for 30 min at room temperature. Negative controls were performed with the corresponding isotype controls of primary antibodies used. The slides were mounted with DAPI Fluoromount-G (SouthernBiotech, Montrouge, France). Images were acquired with a Leica TCS SP2 DMRE confocal-scanning microscope (Leica Microsystems, Nanterre, France) equipped with 40Â and 63Â immersion objectives.
Time-Lapse Microscopy
Murine splenic CD4 + T cells were first stained with CFSE, according to the manufacturer's recommendations (Invitrogen) and then with www.moleculartherapy.org rat anti-mouse CD4-APC (RM4-5, BD Biosciences) mAb. After staining, cells were incubated in ibidi's m-Dish (ibidi, Nanterre, France) in the thermo-regulated chamber of the Zeiss Axiovert 100M confocal microscope. A time-lapse acquisition was performed with a delay of 120 s between frames. Each frame was illuminated using 488-nm and 633-nm lasers, and fluorescence was collected using 505-to 580-nm and 644-to 719-nm filters. The magnification was 40Â/1.3 oil, and images were saved as 8 bits. The image stack was splitted using ImageJ, v1.43, and images were analyzed using CellProfiler 2.0.10415. The cell segmentation was performed on the CFSE fluorescence, and the fluorescence of the CD4 staining was analyzed using R software. Intensity was normalized to the maximum fluorescence measured at t0 for each condition.
In Vivo Chemiluminescence Imaging of Localized Inflammation
After mouse isofluorane anesthesia, 100 mL L-012 solution (15 mg/mL) (Wako, Osaka, Japan) was administered i.v. in retroorbital sinus 4 days after the first MnTBAP injection. At 2 min after L-012 administration, mice were placed in an in vivo imaging system (IVIS Lumina, PerkinElmer, Waltham, MA, USA), and chemiluminescence images were acquired for each mouse with a typical exposure time of 5 min. Images were quantified using LivingImage (PerkinElmer, Waltham, MA, USA) software, by drawing a region of interest (ROI) around the left inferior limb of the mouse. Radiance (ph/s/cm 2 /sr) was measured for each ROI.
Culture and Transduction of Human Primary Cells
CD3
+ T cells, from peripheral blood of healthy individual donors, obtained from the French Blood Establishment (EFS, Evry, France) following institutional agreements, were purified by positive selection via MACS beads using a magnetic cell sorting system (Miltenyi Biotec). CD3 + T cells were activated for 3 days at 37 C, 5% CO 2 in plates coated with anti-CD3 (10 mg/mL) and anti-CD28 (10 mg/mL) antibodies (both from Miltenyi Biotec) and filled with RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 100 U/mL penicillin/streptomycin, 2 mM glutamax, and 100 IU/mL interleukin-2 (IL-2) (Miltenyi Biotec). Cells were then transferred on retronectin (20 mg/cm and expressed from the CMV promoter. 22 For the rAAV1_CMV_mSEAP vector, the pGG2-CMV-muSeAP plasmid encoding the mSEAP under the control of the CMV-IE promoter was used.
39 rAAV1 vectors were purified by centrifugation over a
CsCl gradient and titered in vg by real-time PCR as previously described. 39 Vector final suspension was tested for endotoxin level and found to be <10 EU/mL.
OVA Peptide s.c. Immunization
A mixture of OVA peptides was administrated in a s.c. injection in mice anesthetized by i.p. injection of xylazine (10 mg/kg) and ketamine (100 mg/kg). Two hours after the first i.p. injection of MnTBAP, mice were anesthetized by an i.p. injection of xylazine (10 mg/kg) and ketamine (100 mg/kg), and 25 mL rAAV1_CMV_SGCA_HY viral preparation containing 2.5 Â 10 9 vg was injected in the left TA muscle. Controls were injected with PBS.
Mice were sacrificed 15 days after vector injection, and the injected muscles were harvested to perform histologic analysis. Spleens were harvested to analyze transgene-specific T cell response.
i.v. Injection
Two hours after the first i.p. injection of MnTBAP, mice were anesthetized by an i.p. injection of xylazine (10 mg/kg) and ketamine (100 mg/kg), and 200 mL rAAV1_CMV_SGCA_HY viral preparation containing 2.5 Â 10 9 vg was injected into retro-orbital sinus or into tail vein. Controls were injected with PBS. Serum samples were harvested at day 21 and day 28 post-vector injection to analyze capsidspecific humoral response.
Readministration Protocol
After the initial i.v. injection of rAAV1_CMV_SGCA_HY vector at day 0 (2 h post-first i.p. injection of MnTBAP), the second rAAV1 injection (2 Â 10 9 vg of rAAV1_CMV_mSEAP) was performed 28 days later in the left TA muscle. Mice were followed up to 93 days after readministration to analyze capsid-specific humoral response and to measure circulating mSEAP from serum samples. Mice were killed 93 days after the second injection of vector. Left and right TA muscles were harvested for histological and enzymatic assay.
Histologic Analysis
Mice were killed at indicated time points. Injected muscles were harvested, snap frozen in isopentane previously chilled in liquid nitrogen, and kept at À80 C until processing. Transverse cryosections (8 mm thick) of the muscles were either stained with H&E to evaluate inflammation and muscle integrity or used for colorimetric immunostaining or for mSEAP detection.
For colorimetric immunodetection of CD8a, cryosections were rehydrated with PBS for 5 min and then incubated 20 min with H 2 O 2 to inhibit endogenous peroxidases at room temperature (RT). After washing with PBS, sections were blocked with PBS with 10% goat serum for 30 min and then incubated with 1/40 dilution of a rat monoclonal primary antibody directed against CD8a (Thermo Fisher Scientific) for 1-2 h at RT. After washing with PBS, sections were incubated with secondary antibody goat anti-rat conjugated with horseradish peroxidase (HRP) (Invitrogen) diluted 1/600 for 1 h at RT. Sections were washed three times with PBS and then incubated with diluted diaminobenzidine (Dako, Trappes, France) for 2-5 min. Then, sections were successively treated with ethanol (5 min), twice in xylene (5 min), and mounted with Eukkit (Labonord, VWR International, Fontenay-sous-Bois, France). The slides were examined with a Nikon microscope (Champigny sur Marne, France). Digital images were captured using a charge-coupled device (CCD) camera (Sony) and processed using Cartograph 5.5 (Microvision Software; Microvision, Evry, France).
For mSEAP histochemical detection, transverse cryosections of TA muscles were fixed in 0.5% glutaraldehyde and washed twice with PBS. Endogenous alkaline phosphatase was heat inactivated for 30 min at 65 C. Sections were then incubated for 5 h at 37 C in 0.165 mg/mL 5-bromo-4-chloro-3-indolyl phosphate and 0.33 mg/ mL of nitroblue tetrazolium in 100 mM Tris-HCl, 100 mM NaCl, and 50 mM MgCl 2 . Sections were counterstained with Nuclear Fast Red.
Measure of Transgene and CD8 Expression by Real-Time RT-PCR
Total RNA was extracted from muscles using TRIzol (Invitrogen). Residual DNA was removed from the samples using the Free DNA removal kit (Ambion, Courtaboeuf, France). cDNA was synthesized from 1 mg RNA using a mix of random hexamers and anchored oligo(dT) 3:1 according to the protocol for the Thermo Scientific Verso cDNA Synthesis Kit (Thermo Fisher Scientific). Real-time PCR was performed using the ABI PRISM 7900 system (Life Technology, Saint Aubin, France) with 0.2 mM of each primer and 0.1 mM of the probe according to the protocol for the ABsolute qPCR ROX Mix (Thermo Fisher Scientific). The primer pairs and TaqMan probes used for ha-sarcoglycan amplification were as follows: 920hasarco.F: 5 0 -TGCTGGCCTATGTCATGTGC-3 0 , 991hasarco.R: 5 0 TCTGGAT GTCGGAGGTAGCC-3 0 , and 946hasarco.P: 5 0 -CGGGAGGGAAG GCTGAAGAGAGACC-3 0 . The ubiquitous acidic ribosomal phosphoprotein (PO) gene was used to normalize the data across samples. The primer pairs and TaqMan probe used for PO mRNA amplification were as follows: m181PO.F: 5 0 -CTCCAAGCAGATGCAGC AGA-3 0 , m267PO.R: 5 0 -ACCATGATGCgCAAGGCCAT-3 0 , and m225PO.P: 5 0 -CCGTGGTGCTGATGGGCAAGAA-3 0 . The primer pairs and TaqMan probes for the mouse CD8a were Mm01182107_g1 (Thermo Fisher Scientific).
Genomic DNA Extraction and Quantitative Real-Time PCR Genomic DNA was extracted from frozen muscles using a MagNA Pure 96 Instrument (Roche). Real-time PCR to amplify CMV in relation to the titin gene was performed using the ABI PRISM 7900 system (Life Technology, Saint Aubin, France) with 0.1 mM of each primer and 0.1 mM of the probe according to the protocol for the ABsolute qPCR ROX Mix (Thermo Fisher Scientific, Cambridge, UK). The primer pairs and TaqMan probes used for CMV and titin gene amplification were as follows: mTitin-F: 5 0 -AAAACG AGCAGTGACGTGAGC-3 0 , mTitin-R: 5 0 -TTCAGTCATGCTGC TAGCGC-3 0 , and mTitin-P: 5 0 -TGCACGGAAGCGTCTCGTCTCA GTC-3 0 ; mCMV-F: 5 0 -CATCAATGGGCGTGGATAGC-3 0 , mCMV-R: 5 0 -GGAGTTGTTACGACATTTTGGAAA-3 0 , and mCMV-P: 5 0 -ATTTCCAAGTCTCCACCC-3 0 . Results were calculated from a standard curve based on dilutions of 2 plasmids containing either the Titin or CMV sequences. Background levels ranged between 36 and 40 CT values.
IFN-g ELISPOT
Spleens were harvested to analyze the cellular immune anti-transgene response by T cell cytokine response assay. MultiScreen-HA Assay System 96-well filtration plates (Merck) were coated overnight with 2.5 mg/mL anti-mouse IFN-g purified mAbs (eBioscience) at 4 C, washed, and then blocked with RPMI 1640 medium (Life Technologies, Saint Aubain, France) supplemented with 10% heat-inactivated FCS (Life Technologies), 100 U/mL penicillin/streptomycin (Thermo Fisher Scientific), and 2 mM GlutaMAX-I (Life Technologies) for 2 h at 37 C. Plates were washed three times with RPMI 1640 medium without FCS. Splenocytes were added in duplicate to the IFN-gcoated well (1 or 0.5 Â 10 6 cells per well) and cultured in the presence of Dby and Uty peptides (GENEPEP, Montpellier, France) at 2 mM or in the presence of OVA peptides at 10 mg/mL. As a positive control, cells were stimulated with concanavalin A (Sigma-Aldrich) at 1 mg/mL in each test. After 24 h, plates were washed three times with PBS and 0.05% Tween 20 and three times with PBS alone before a 2-h incubation at RT with 1 mg/mL biotinylated anti-mouse IFN-g mAb in PBS/0.1% BSA. Plates were washed three times with PBS/0.05% Tween 20 and three times with PBS alone before incubation for 1 h and 30 min with 0.66 U/mL streptavidin-alkaline phosphatase (AP) conjugate (Roche Diagnostics, Mannheim, Germany) at RT. After wash step with PBS/0.05% Tween 20, and with PBS alone, spots were developed using BCIP/NBT-plus (Mabtech, Nacka Strand, Sweden). Spots were counted using an AID reader (Cepheid Benelux, Louven, Belgium). Spot-forming units (SFUs) per million cells for each mouse were calculated as the average value of duplicate measures after subtraction of background values obtained with in vitro unstimulated splenocytes.
Measurement of Anti-AAV1 Antibody Titers rAAV1-specific serum antibody titers were evaluated by ELISA. F96 Nunc Maxisorp Immuno Plates (Thermo Fisher Scientific) were coated overnight at 4 C with 0.2 Â 10 9 vg of AAV1 vector diluted in 0.1 M carbonate coating buffer (pH 9.6). Plates were washed three times and blocked with a solution of 6% milk in PBS for 2 h at RT. Serial dilutions of samples in this blocking buffer (10-fold dilutions starting 10
À2 to 10 À5 were tested) were incubated on the plates for 1 h at 37 C. Plates were washed three times, incubated with a horseradish-peroxidase-conjugated goat antibody directed against mouse IgG (Southern Biotech, Birmingham, AL, USA), and revealed by the TMB Substrate Reagent Set (BD Biosciences). Reaction was stopped with an H 2 SO 4 solution, and the optical density at 450 nm was determined using a luminometer (Discovery HT-R, BioServ, Thiais, France) with KC4 software. The area under the curve (AUC) values obtained from the optical densities at four dilution points were calculated for statistical analysis using GraphPad Prism software (Logi Labo, Paris, France).
Quantification of Circulating mSEAP
Determination of alkaline phosphatase concentration in immunized mice sera was performed by chemiluminescence analysis. 39 Blood samples were centrifuged for 10 min at 8,000 rpm to collect sera, endogenous alkaline phosphatase was heat inactivated for 5 min at 65 C, and the heat-resistant mSEAP was measured by addition of the reaction buffer and CSPD chemiluminescent substrate, according to the manufacturer's instructions (Tropix, Applied Biosystems, Foster City, CA, USA). Chemiluminescence was quantified using an EnSpire luminometer (PerkinElmer, Waltham, MA, USA). Expression levels are expressed as nanograms of mSEAP per milliliter of serum using a standard curve of purified human placental alkaline phosphatase.
Statistics
Statistical analyses were performed using GraphPad Prism 5 software. For antibody production, differences were analyzed by comparing the average values of the AUC for the titration of each mouse serum. Significant differences were defined with probability values inferior to 0.05 (*p < 0.05, **p < 0.005, and ***p < 0.001). 
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